Objective To observe the long-term clinical effects of Fogarty catheter on arteriovenous fistula thrombosis and reperfusion rate in patients on hemodialysis. Methods The thrombosed vascular access was incised and F4 or F5 Fogarty catheter was inserted. After the Fogarty catheter passed through the thrombus, the heparin saline was infused into the balloon and then the catheter was pulled back. All the patients were followed up for 5-48 months. Results In 14 cases of total 15 patients embolisms were removed successfully and the blood flow during hemodialysis reached more than 200 ml/min. The catheter use time was (21.5±15.4) months in average and the longest use time was 48 months. Conclusions The recent and long-term effects of Fogarty catheter is good for arteriovenous fistula thrombosis, which prolongs the use period of autologous arteriovenous fistula and is worthy to be popularized.

Objective: To compare the difference of infrared radiation temperature on body surface of points between healthy people and patients with hyperplasia of mammary glands. Method: The thermaCATMT P30 infrared thermal imaging system was selected to measure the infrared radiation temperature on body surface of eight points in four meridians in 74 patients with hyperplasia of mammary glands and 63 healthy people. Results: The infrared radiation temperatures on body surface of right Youmen (KI 21) in cases with hyperplasia of mammary glands were significantly higher than the healthy people (P=0.009), and the infrared radiation temperatures on left Youmen (KI 21) and other points had no significant difference with healthy people (P>0.05). Conclusion: The infrared radiation temperatures on body surface of right Youmen (KI 21) have significant differences with healthy people. This might occur because of the pathogenesis of hyperplasia of mammary glands and of the specificity of the point Youmen (KI 21).

ONYX-015 and H101 are E1B 55-kDa protein-deficient replicating C group adenoviruses that are currently in clinical trials as antitumor agents. However, their application in cancer gene therapy is limited by the native tropism of C group adenoviruses. This is in part due to low expression of the C group adenovirus receptor (coxsackievirus-adenovirus receptor, CAR) on malignant tumors. An H101-based chimeric virus vector containing sequences encoding the Ad35 fiber domain instead of the Ad5 fiber (H101-F35) was constructed. This modification allowed infection of tumor cells through CD46, a membrane protein over-expressed on tumors. The CAR and CD46 RNA expression was evaluated by RT-PCR method. H101-F35 conferred a stronger cytocidal effect than H101 and ONYX-015 in tumor cell lines that lacked CAR expression (MDA-MB-435 and MCF-7), while the cytocidal effect of H101-35, H101 and ONYX-015 was similar in high-level CAR expressing cancer cell lines (A549, NCI-H446, Hep3B, LNCaP, ZR-75-30 and Bcap-37). In an MDA-MB-435 xenograft mouse tumor model, tumor growth in mice receiving H101-F35 was significantly inhibited compared with mice injected with H101. These results suggest that the chimeric oncolytic adenovirus H101-F35 vector might be a useful candidate for gene therapy of cancer.

ObjectiveTo evaluate the clinical efficacy and safety of the traditional Chinese medicine （TCM） compound Chaiqin Xiaoyong Decoction （柴芩消痈饮， CXD） combined with Jinhuang Ointment （金黄膏， JO） in treating the nodular stage of acne mastitis of liver meridian heat accumulation type. MethodsA randomized， double-blind， placebo-controlled clinical trial was conducted. A total of 108 patients with liver meridian heat accumulation type acne mastitis in the nodular stage were randomly assigned to a treatment group and a control group， with 54 patients in each group. Both groups received topical application of JO once daily at a thickness of 3~5 mm for 8 hours， along with standard nursing care. On this basis， the treatment group received oral CXD granules， while the control group received placebo granules， administered twice daily， 3 sachets per dose， for 14 consecutive days. Clinical efficacy， TCM symptom scores， nodule size， visual analogue scale （VAS） pain scores， white blood cell （WBC） count， C-reactive protein （CRP） level， and systemic immune-inflammation index （SII） were compared. At the end of treatment， efficacy and safety indicators were evaluated. A 6-month follow-up was conducted to compare the proportion of patients undergoing surgical treatment. ResultsThe total clinical efficacy rate in the treatment group was 90.38% （47/52）， significantly higher than 32.00% （16/50） in the control group （P＜0.01）. The treatment group also showed significantly lower TCM symptom scores， VAS scores， nodule size， WBC count， CRP level， and SII （P＜0.05 or P＜0.01）. During follow-up， the surgical intervention rate in the treatment group was 5.77% （3/52）， lower than 14.00% （7/50） in the control group， with a statistically significant difference （P＜0.01）. No significant abnormalities were observed in safety indicators before and after treatment in either group. ConclusionCXD effectively reduces nodule size and alleviates symptoms such as redness and pain in patients with acne mastitis of liver meridian heat accumulation type， improves TCM symptom scores， enhances overall clinical efficacy， and demonstrates good safety.